二期试验患者口服卡培他滨铂和紫杉烷耐火卵巢、输卵管、腹腔癌症。

文章的细节

引用

复制到剪贴板

狼JK, Bodurka直流,Verschraegen C,太阳CC, Branham D,詹金斯广告,阿特金森N, Gershenson DM

二期试验患者口服卡培他滨铂和紫杉烷耐火卵巢、输卵管、腹腔癌症。

Gynecol杂志。2006年9月,102 (3):468 - 74。doi: 10.1016 / j.ygyno.2005.12.040。Epub 2006年3月3。

PubMed ID

16516276 (在PubMed

]

文摘

目的:确定功效、毒性和卡培他滨(Xeloda)的生活质量,患者口服5 -氟尿嘧啶衍生物,chemorefractory缪氏癌症复发。患者和方法:患者chemorefractory持续或复发性卵巢,输卵管或腹膜癌与可衡量的疾病被录取。卡培他滨是口头管理开始在2000 mg / m2 /日,分两次在吃饭上21天的循环:14天卡培他滨,后跟一个7天的休息时间。一剂增加或减少是允许的。反应是评估后循环2和循环4和每三周期。可评价的疾病的标准评价包括二维测量。标准的标准反应。治疗停止后如果进展发生至少两个周期的治疗。生活质量和症状进行评估。结果:41例患者登记。 Ninety-two percent of patients had >2 previous chemotherapy regimens. All patients had platinum- and taxane-resistant disease. Thirty-six patients were evaluable for response. Three patients had a partial response, with a median response duration of five cycles. Twenty-two patients had stable disease for 3 to 11 cycles (median, 6 cycles). Eleven had progressive disease. The only grade 4 toxicity was abdominal pain (n = 2). The most common grade 3 toxicities were fatigue (n = 19), hand-foot syndrome (n = 11), abdominal pain (n = 7), and diarrhea (n = 4). One patient had a grade 3 hematologic toxicity (anemia). CONCLUSION: Capecitabine at the dosages used in this study is well tolerated and has minimal hematologic toxicity.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

卡培他滨